MX376112B - Derivados fusionados tricíclicos de 1-(ciclo)alquil piridin-2-ona como compuestos inhibidores de la familia bet de bromodominios, y el uso de los mismos en el tratamiento de trastornos proliferativos o cáncer. - Google Patents

Derivados fusionados tricíclicos de 1-(ciclo)alquil piridin-2-ona como compuestos inhibidores de la familia bet de bromodominios, y el uso de los mismos en el tratamiento de trastornos proliferativos o cáncer.

Info

Publication number
MX376112B
MX376112B MX2017012387A MX2017012387A MX376112B MX 376112 B MX376112 B MX 376112B MX 2017012387 A MX2017012387 A MX 2017012387A MX 2017012387 A MX2017012387 A MX 2017012387A MX 376112 B MX376112 B MX 376112B
Authority
MX
Mexico
Prior art keywords
bromodomains
treatment
alkylpyridin
cyclo
cancer
Prior art date
Application number
MX2017012387A
Other languages
English (en)
Spanish (es)
Other versions
MX2017012387A (es
Inventor
Chandrika Mulakala
Dhanalakshmi Sivanandhan
Murugan Chinnapattu
Pavan Kumar Gondrala
Sridharan Rajagopal
Saravanan Vadivelu
Original Assignee
Jubilant Biosys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Biosys Ltd filed Critical Jubilant Biosys Ltd
Publication of MX2017012387A publication Critical patent/MX2017012387A/es
Publication of MX376112B publication Critical patent/MX376112B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017012387A 2015-03-30 2016-03-30 Derivados fusionados tricíclicos de 1-(ciclo)alquil piridin-2-ona como compuestos inhibidores de la familia bet de bromodominios, y el uso de los mismos en el tratamiento de trastornos proliferativos o cáncer. MX376112B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1636CH2015 2015-03-30
PCT/IN2016/050098 WO2016157221A1 (en) 2015-03-30 2016-03-30 Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2017012387A MX2017012387A (es) 2018-06-11
MX376112B true MX376112B (es) 2025-03-07

Family

ID=56015058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012387A MX376112B (es) 2015-03-30 2016-03-30 Derivados fusionados tricíclicos de 1-(ciclo)alquil piridin-2-ona como compuestos inhibidores de la familia bet de bromodominios, y el uso de los mismos en el tratamiento de trastornos proliferativos o cáncer.

Country Status (16)

Country Link
US (2) US10689390B2 (https=)
EP (1) EP3277683B1 (https=)
JP (1) JP6764877B2 (https=)
KR (1) KR102588109B1 (https=)
CN (1) CN107548393B (https=)
AU (1) AU2016242473B2 (https=)
BR (1) BR112017020739B1 (https=)
CA (1) CA2980266C (https=)
DK (1) DK3277683T3 (https=)
ES (1) ES2911886T3 (https=)
IL (1) IL254528B (https=)
MX (1) MX376112B (https=)
PL (1) PL3277683T3 (https=)
PT (1) PT3277683T (https=)
RU (1) RU2721120C2 (https=)
WO (1) WO2016157221A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100277T1 (it) * 2015-09-09 2021-07-12 Jubilant Biosys Ltd Derivati triciclici fusi di piridina-2-0ne e loro uso come inibitori di brd4
CA3045855A1 (en) * 2016-11-10 2018-05-17 Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof
WO2019214399A1 (zh) * 2018-05-10 2019-11-14 罗欣药业(上海)有限公司 苯并七元杂环类化合物、其制备方法、药物组合物及应用
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1545767A (en) * 1976-06-30 1979-05-16 Aspro Nicholas Ltd Isoquinoline derivatives
WO2008133288A1 (ja) 2007-04-25 2008-11-06 Daiichi Sankyo Company, Limited 三環性アリール化合物
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
US9085582B2 (en) 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CA2901352A1 (en) * 2013-02-19 2014-08-28 Bayer Pharma Aktiengesellschaft Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
WO2014139324A1 (en) * 2013-03-12 2014-09-18 Abbvie Inc. Tetracyclic bromodomain inhibitors
WO2015018520A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
US9814728B2 (en) * 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)

Also Published As

Publication number Publication date
EP3277683B1 (en) 2022-03-09
JP2018510203A (ja) 2018-04-12
NZ735972A (en) 2024-08-30
KR102588109B1 (ko) 2023-10-12
AU2016242473A1 (en) 2017-10-26
DK3277683T3 (en) 2022-05-02
PL3277683T3 (pl) 2022-05-23
CN107548393A (zh) 2018-01-05
US11319326B2 (en) 2022-05-03
RU2017135205A (ru) 2019-04-10
BR112017020739A2 (pt) 2018-07-17
PT3277683T (pt) 2022-06-28
CN107548393B (zh) 2021-03-02
IL254528B (en) 2020-11-30
EP3277683A1 (en) 2018-02-07
IL254528A0 (en) 2017-11-30
RU2017135205A3 (https=) 2019-07-17
RU2721120C2 (ru) 2020-05-15
BR112017020739B1 (pt) 2023-03-14
US20200331926A1 (en) 2020-10-22
ES2911886T3 (es) 2022-05-23
US20180282345A1 (en) 2018-10-04
CA2980266A1 (en) 2016-10-06
JP6764877B2 (ja) 2020-10-07
US10689390B2 (en) 2020-06-23
AU2016242473B2 (en) 2020-06-25
HK1248686A1 (zh) 2018-10-19
MX2017012387A (es) 2018-06-11
KR20170132278A (ko) 2017-12-01
WO2016157221A1 (en) 2016-10-06
CA2980266C (en) 2025-05-06

Similar Documents

Publication Publication Date Title
MX382128B (es) Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4.
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
MX382331B (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina útiles en el tratamiento del cáncer.
MX393395B (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.
PH12016501440A1 (en) Novel heterocyclic compounds
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
WO2015058126A8 (en) Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015058163A3 (en) Heteromaromatic compounds useful for the treatment of prolferative diseases
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MX390747B (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
WO2015191754A3 (en) Phosphatidylinositol 3-kinase inhibitors
MX376112B (es) Derivados fusionados tricíclicos de 1-(ciclo)alquil piridin-2-ona como compuestos inhibidores de la familia bet de bromodominios, y el uso de los mismos en el tratamiento de trastornos proliferativos o cáncer.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
WO2018083635A3 (en) Tricyclic heterocyclic derivatives and uses thereof
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
EA201691920A1 (ru) Новые конденсированные соединения имидазобензотиазола
MX2018014165A (es) Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion.
BR112017013731A2 (pt) composto heterocíclico selecionado dentre os compostos de fórmula geral, composição farmacêutica, e, uso cosmético de um composto de fórmula geral
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний

Legal Events

Date Code Title Description
FG Grant or registration